![A Killer Illness ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Recommended
More Related Content
Similar to Precysion Glss Presentation Oct Pm2
Similar to Precysion Glss Presentation Oct Pm2 (20)
Precysion Glss Presentation Oct Pm2
- 1. SEPSIS A Killer Illness Paul McMahon
- 5. “ PRECYSION” A Paradigm Shift Patent Pending Diagnostic and Prognositc Tool Using Genetic Biomarkers (Cytokine Gene Expression). Developed by St James Hospital & Trinity College Dublin To screen patients & accurately predict those susceptible to Sepsis post surgery. Majority will tolerate infection without critical illness. To optimise individual treatment, care stratification. Identify groups with Sepsis at low, intermediate & high risk.
- 12. Save Lives/Reduce Healthcare Costs In Multi-Billion Market JV & Investment Partner Needed! Phase 1 ; €0.5m EU Market Prototype Phase 2; €3.5m Enter US Market PoC (EI/TCD) Oct ‘09
Editor's Notes
- Good day! Thank you for your attention. Today I would like to introduce you to my project on the EI Business Partner programme in collaboration with research work from St James Hospital and TCD.
- Sepsis is an overwhelming systemic inflammatory response to infection such as pneumonia, urinary tract, wound or skin leading to blood poisoning, chronic organ failure and death in 30% of cases. 2~3 people in every 1,000 of our population develop Sepsis and 1,400 die daily from it. In America historically the number of cases of Sepsis are 750,000 pa with Europe having equivalent figures. US hospital records from 1979 to 2000 show that Sepsis is on the rise at 13% pa due to wider invasive surgical procedures, more resistant micro organisms, more suppressed immune systems and an ever aging population.
- Both in human life and healthcare resource terms Sepsis is a costly illness with an annual cost to Western economies estimated at €45 billion. Sepsis is currently very difficult to diagnose and differentiate from other forms of critical illness and bacterial infection. Rapid and accurate diagnosis is key to patient outcome with cautious GP’s and Consultants admitting patients to the ICU unit for monitoring. The average cost per patient admitted to ICU is €2,500 per day for an average stay of 20 days in excess of €50,000 when drug treatments at €10,000 plus are added in. Survivors can spend up to a year or more in care. Only 50% fully recover. Insurance re-imbursement costs are also an issue in the case of misdiagnosis.
- So what is missing right now! Opinion leaders agree that the number of Sepsis cases is increasing and that the rate of mortality is staying stubbornly high at 25~30%. The current tests are not working to reduce the levels and the costs of Sepsis treatment, rather they are designed only to detect the source of the infection post onset when the patient has reached a critical stage of treatment. What is now needed is a test based on genetic biomarkers that tracks a person’s genetic susceptibility, state of immune system strength and coexisting complications in other to define an accurate prognosis.
- Today I am pleased to introduce you to Precysion a patent pending Diagnostic and Prognostic Tool based on Genetic Biomarkers from TCD and St James that accurately predicts those at greater risk of succumbing to Sepsis. In the majority of cases patients will tolerate infection without succumbing to critical illness but the difficulty is identifying those with Sepsis once fever and other symptoms show. Precysion accurately measures the levels and ratios of immune system proteins called cytokines which orchestrate the bodies pro-inflammatory and anti-inflammatory defences. The studies at St James Hospital show that the ratio of cytokines such as TNF Alpha, Interferon Gamma and various Interleukins accurately identify those patient groups who will tolerate infection without becoming critically ill. Furthermore in those who do develop overwhelming illness the test is able to identify those groups at low risk, intermediate risk and high risk of death. In some cases the likelihood of developing critical illness is 9~10 times greater than the average.
- The market for genetic biomarkers is growing at 18% per annum and is expected to reach $12.7 billion in 2012. Of this the market for diagnostic applications is expected to reach $5,15 billion in 2012. Other diagnostic applications include HIV, Hepatitus, Meningitus and TB. The number of Sepsis cases in the US is expected to reach one million in 2010 with an average ICU cost of $30,000 +. The European market is similar. For each case of a patient presenting with Sepsis there may be a factor of 3~4 presenting with infection who do not develop Sepsis but who still require investigation, testing and therapy. Therefore the potential market for a Sepsis kit test in hospitals not including clinical trials and drug development is 8 million kits in the US & EU. /if we look at the cost per test for a Sepsis pathogen detection product such as Septifast which is marketed at $180 we could expect to a similar price of €150 for Precysion. This would lead to a potential market for hospital kits of €12 Billion.
- Obtain “Proof of Concept” data later this month. Verify route to market with hospital testing protocols, lab equipment platforms, EU & US validation procedures. Establish spin out company. Reduce the current 20+ step lab process to a commercial test kit prototype. Check out platform partners and prospective JV partners. Go to market in the next 2~3 years.
- Dr Thomas Ryan is the Consultant Anaesethist in charge of accident and emergency care in St James Hospital. He and his research team are the founders of the technology. Tom has also spent time as a fellow in the famous Cleveland Clinic in Ohio. Dr John Thornback is an expert in “Genetic Biomarkers” and Nuclear Science. John worked with Professor Sir Geoffrey Wilkinson who won the Nobel Prize for Chemistry and his work on atomic science in the 70’s. John has worked at Harvard University and MIT and has been active in the COO and CSO role in a number of multinational and start up diagnostic companies. Bruce Murdoch is a colleague of mine who as acted as VP and MD for a number of multinational and start up biopharma and diagnostic companies. Ono of his roles with Bioaccelerate Inc. a $120 million turnover company was to identify, fund and advise suitable biotech start up projects. Clive Kendall qualified with Deloitte Plender Griffiths, and gained further experience at Hill Samuel and Arthur Andersen. He has been Finance Director of two Companies listed on the London Stock Exchange. As a business advisor and an Interim Manager he has had significant senior level involvement with businesses ranging from start up to £500m turnover, both private and public. I myself have been involved in start up companies since I graduated and received a scholarship to Japan in the late eighties. I was part of the start up team for 2 Japanese mfg facilities in the UK. I went on to start up a systems integration business in Dublin which was sold for €9 million in 2000. I went on to work with 5 start up companies in the life sciences arena including diagnostics, stem cell storage and manufacturing control systems.
- Speak about what phase one and two are with this slide.